Incannex Healthcare Inc.

IXHL ·Healthcare, Drug Manufacturers - General
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023
Revenue $86.0K $12.0K
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $10.7M $12.9M $6.3M
SG&A Expense $13.1M $17.2M $8.0M
Operating Income $-23.8M $-30.0M $-49.7M
Operating Margin -27,661.6% -250,341.7%
Interest Expense
Pretax Income $-46.9M $-18.4M $-48.8M
Income Tax Expense $30.0K
Net Income $-46.9M $-18.5M $-48.8M
Net Margin -54,517.4% -153,825.0%
EPS (Basic) $-1.35 $-0.58 $-1.66
EPS (Diluted) $-1.35 $-0.58 $-1.66
Shares Outstanding (Basic) 34.5M 32.3M 30.8M
Shares Outstanding (Diluted) 34.5M 32.3M 30.8M
Dividends Per Share